Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study.
- Author:
Ines GOCKEL
1
;
Boris JANSEN-WINKELN
;
Linda HAASE
;
Philipp RHODE
;
Matthias MEHDORN
;
Stefan NIEBISCH
;
Yusef MOULLA
;
Orestis LYROS
;
Florian LORDICK
;
Katrin SCHIERLE
;
Christian WITTEKIND
;
René THIEME
Author Information
- Publication Type:Original Article
- Keywords: Gastric cancer; Peritoneal metastasis; PIPAC; Palliative chemotherapy
- MeSH: Ascites; Carcinoma; Cisplatin; Data Collection; Doxorubicin; Drug Therapy*; Humans; Neoplasm Metastasis*; Prognosis; Prospective Studies; Quality of Life; Stomach Neoplasms*
- From:Journal of Gastric Cancer 2018;18(4):379-391
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Gastric cancer (GC) patients with peritoneal metastasis (PM) have poor prognosis. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with systemic chemotherapy is a novel treatment option for patients in stage IV of the disease. MATERIALS AND METHODS: Between November 2015 and June 2018, prospective data collection was performed in 24 patients with GC and PM (median age, 57; range, 44–75 years). These patients underwent 46 PIPAC procedures with a median number of 2 interventions per patient (range, 1–6). A laparoscopic access was used and a combined therapy of cisplatin and doxorubicin aerosol was administered. RESULTS: The median peritoneal carcinomatosis index before the 1st PIPAC was 14 (range, 2–36), and the median ascites volume in patients before the 1st PIPAC was 100 mL (range, 0–6 mL, 300 mL). Eleven patients, who received 2 or more PIPAC procedures, had decreased and stable volumes of ascites, while only 3 patients displayed increasing volume of ascites. The median overall survival was 121 days (range, 66–625 days) after the 1st PIPAC procedure, while 8 patients who received more than 3 PIPAC procedures had a median survival of 450 days (range, 206–481 days) (P=0.0376). CONCLUSIONS: Our data show that PIPAC is safe and well tolerated, and that the production of ascites can be controlled by PIPAC in GC patients. Patients, who received 2 or more PIPAC procedures, reported a stable overall quality of life. Further studies are required to document the significance of PIPAC as a palliative multimodal therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03100708
